LGVN News and Press, Longeveron Inc. From 06/11/24

With current HLHS treatment, only 50-60% of infants survive to adolescence In ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B™ compared to approximate 20% mortality rate observed from historical c...

Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. The company today announced the launch of its contract development and manufacturing business at its 15,000-square-fo...

2024-06-03 09:33:10 ET More on Longeveron Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript Longeveron announces board transitions Longeveron stock rallies 85% on Alzheimer's presentation (update) Seeking Alpha’s Quant Rating on Longeveron ...

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics MIAMI, June 03, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a cl...

Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at next month’s 2024 BIO International Convention; the convention is scheduled to take plac...

MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company will participate in the BIO Internat...

2024-05-17 23:08:05 ET Longeveron Inc. (LGVN) Q1 2024 Earnings Conference Call May 14, 2024, 05:00 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - Chief Medical Officer Lisa Locklear - CFO Joshua Hare...

2024-05-15 08:31:48 ET More on Longeveron Longeveron announces board transitions Longeveron stock rallies 85% on Alzheimer's presentation (update) Seeking Alpha’s Quant Rating on Longeveron Historical earnings data for Longeveron Read the ful...

Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...